ANKRD31

Across TCGA pan-cancer cohorts, ANKRD31 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD31 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD31 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD31 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

UCEC, BRCA, and SCLC are the cancer types where ANKRD31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.964	0.623	.010	28	view →
BRCA	DFS	Median	All	0.679	0.903	.031	8	view →
SCLC	DFS	Median	II,III,IV	1.000	0.419	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ANKRD31–UCEC (DFS)

Open the UCEC breakdown →